TY - JOUR
T1 - Progress in myelodysplastic syndromes.
AU - Garcia-Manero, Guillermo
N1 - Funding Information:
Dr. Garcia-Manero has received research funding from Eisai Inc.; Celgene Corporation; Merck & Co., Inc.; and Novartis Pharmaceuticals Corporation.
Funding Information:
Supported in part by grants 5PO1CA108631 and the Leukemia and Lymphoma Society of America.
PY - 2009
Y1 - 2009
N2 - During the past 5 years, we have witnessed an explosion in our understanding, classification, and number of therapeutic opportunities for patients with myelodysplastic syndromes (MDS). These include the development of new histologic classifications, scoring systems, supportive care measures, and most importantly, effective treatments that are safe and can modify the natural history of this complex group of hematopoietic disorders. In this brief review, and as part of the Leukemia 2008, Fourth International Conference, held in Houston during September 2008, I summarize some of the most important recent developments in the field of MDS and try to identify new problems and opportunities for patients and researchers in this area.
AB - During the past 5 years, we have witnessed an explosion in our understanding, classification, and number of therapeutic opportunities for patients with myelodysplastic syndromes (MDS). These include the development of new histologic classifications, scoring systems, supportive care measures, and most importantly, effective treatments that are safe and can modify the natural history of this complex group of hematopoietic disorders. In this brief review, and as part of the Leukemia 2008, Fourth International Conference, held in Houston during September 2008, I summarize some of the most important recent developments in the field of MDS and try to identify new problems and opportunities for patients and researchers in this area.
UR - http://www.scopus.com/inward/record.url?scp=74049086613&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=74049086613&partnerID=8YFLogxK
U2 - 10.3816/clm.2009.s.025
DO - 10.3816/clm.2009.s.025
M3 - Review article
C2 - 19778854
AN - SCOPUS:74049086613
SN - 2152-2669
VL - 9 Suppl 3
SP - S286-292
JO - Clinical lymphoma & myeloma
JF - Clinical lymphoma & myeloma
ER -